Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et åbent, enkeltarmsstudie til evaluering af farmakokinetik og sikkerhed af subkutan sonelokimab hos unge med moderat til svær Hidradenitis Suppurativa (VELA-TEEN)

4. november 2026 opdateret af: MoonLake Immunotherapeutics AG

Et åbent, enkeltarmsstudie til evaluering af farmakokinetikken og sikkerheden af ​​subkutan sonelokimab hos unge i alderen ≥12 til ≤17 år på undersøgelsestidspunktet inklusion med aktiv moderat til svær Hidradenitis Suppurativa

This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

35

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Arkansas
      • North Little Rock, Arkansas, Forenede Stater, 72117
        • Clinical Site
    • California
      • Stanford, California, Forenede Stater, 94304
        • Clinical Site
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20010
        • Clinical Site
    • Florida
      • Hollywood, Florida, Forenede Stater, 33201
        • Clinical Site
      • Miami, Florida, Forenede Stater, 33136
        • Clinical Site
    • Georgia
      • Macon, Georgia, Forenede Stater, 31217
        • Clinical Site
      • Sandy Springs, Georgia, Forenede Stater, 30328
        • Clinical Site
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Clinical Site
    • Indiana
      • Columbus, Indiana, Forenede Stater, 47201
        • Clinical Site
    • Kentucky
      • Murray, Kentucky, Forenede Stater, 42071
        • Clinical Site
    • Michigan
      • Waterford, Michigan, Forenede Stater, 48328
        • Clinical Site
    • North Dakota
      • Fargo, North Dakota, Forenede Stater, 58103
        • Clinical Site
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29425
        • Clinical Site
    • Texas
      • Dallas, Texas, Forenede Stater, 75246
        • Clinical Site
      • Dallas, Texas, Forenede Stater, 75390-8575
        • Clinical Site
      • San Antonio, Texas, Forenede Stater, 78218
        • Clinical Site
    • Virginia
      • Norfolk, Virginia, Forenede Stater, 23502
        • Clinical Site
    • Washington
      • Seattle, Washington, Forenede Stater, 98105
        • Clinical Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år til 17 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Participants must be between ≥12 and ≤17 years of age at the time of signing the informed consent.
  2. Participants who are diagnosed with HS as determined by the investigator and have a history of signs and symptoms of HS for ≥6 months before signing the informed consent.
  3. Participants who have moderate to severe HS as determined by the refined Hurley staging (Stages IB and IC, IIB and IIC, and III).
  4. Participants who have had an inadequate response to appropriate systemic antibiotics for treatment of HS .
  5. Participants must be up to date with age-appropriate vaccine requirements 8 weeks prior to entry in the study.
  6. Participants with a body weight of ≥ 40 kg.

Exclusion Criteria:

  1. Participants with a known hypersensitivity to sonelokimab or any of its excipients.
  2. Participants with a draining fistula count of ≥20 at the Screening Visit.
  3. Participants with any other active skin disease or condition that may, in the opinion of the investigator, interfere with the assessment of HS.
  4. Participants with underlying conditions that, in the opinion of the investigator, potentially compromise the participant and/or places the participant at unacceptable risk.
  5. Participants who have history or concurrent clinically significant medical conditions or any other reason, including any physical, psychological, or psychiatric condition, that in the opinion of the investigator would compromise the safety or interfere with participation in the study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk.
  6. Participants with any other skin disease or other medical condition that in the opinion of the investigator would interfere with an accurate assessment of clinical symptoms of HS.
  7. Participants with a confirmed or suspected diagnosis of inflammatory bowel disease.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: sonelokimab

Subjects will receive sonelokimab 120mg subcutaneously (SC) as an induction regimen of 4 doses, followed by sonelokimab SC every 4 weeks maintenance dose starting at Week 8

Open label

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Pharmacokinetics (PK) of sonelokimab in adolescents
Tidsramme: Week 24

PK (trough concentrations) of sonelokimab over 24 weeks of treatment

Week 24
Adverse events (AEs) following treatment with sonelokimab in adolescents
Tidsramme: Week 24

Incidence, relatedness, severity and seriousness of all AEs over 24 weeks of treatment from baseline

Week 24
Discontinuation of sonelokimab treatment due to AEs
Tidsramme: Week 24

Number of participants discontinued from sonelokimab treatment due to AE over 24 weeks of treatment from baseline

Week 24
Clinically significant changes in clinical laboratory parameters
Tidsramme: Week 24

Number of participants with clinically significant changes in hematology, biochemistry and urinalysis from baseline

Week 24
Clinically significant changes in vital signs
Tidsramme: Week 24

Number of participants with clinically significant changes in vital signs from baseline

Week 24
Clinically significant changes in standard 12-lead electrocardiogram (ECG) intervals
Tidsramme: Week 24

Number of participants with clinically significant changes in 12-lead ECG intervals from baseline

Week 24

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Hidradenitis Suppurativa Clinical Response (HiSCR)75
Tidsramme: Week 24

Percentage of participants achieving a HiSCR75 response over time

Week 24
Hidradenitis Suppurativa Clinical Response (HiSCR) 50
Tidsramme: Week 24

Percentage of participants achieving a HiSCR50 response over time

Week 24
International Hidradenitis Suppurativa Severity Score System (IHS4)
Tidsramme: Week 24

Absolute change in IHS4 score over time

Week 24
Children's Dermatology Life Quality Index (CDLQI)
Tidsramme: Week 24

Percentage of participants achieving a CDLQI total reduction of ≥2.5 over time among participants with a baseline CDLQI ≥2.5

Week 24
Numerical Rating Scale (NRS) 30
Tidsramme: Week 24

Percentage of participants achieving a ≥30% reduction and a ≥2-unit reduction over time in the NRS30 for pain in PGA among participants with a baseline NRS ≥3

Week 24

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. december 2024

Primær færdiggørelse (Faktiske)

28. september 2026

Studieafslutning (Faktiske)

28. september 2026

Datoer for studieregistrering

Først indsendt

29. november 2024

Først indsendt, der opfyldte QC-kriterier

6. januar 2025

Først opslået (Faktiske)

10. januar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner